Jay Shah, MD
Cardiovascular Disease · Valparaiso, INNPI 1134450737
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $83,682 of the $100,468 with a category attached, or 83.3%. Amgen accounts for 80.7% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2021 at $41,967 and has fallen 74.8% since, to $10,584 in 2025. Among cardiovascular disease clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 420 payments — averaging $239.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$81K
- Novartis$13K
- Painteq LLC$782
- Vifor Pharma, Inc.$738
- Johnson & Johnson$657
- AstraZeneca$530
- plus $4K from 23 others
What the payments were for
- Speaking & faculty fees$83,68283%
- Travel & lodging$5,7556%
- Food & beverage$10,91211%
- Education$1190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 117 | $81,125 |
| Novartis | 71 | $12,684 |
| Painteq LLC | 6 | $782 |
| Vifor Pharma, Inc. | 15 | $738 |
| Johnson & Johnson | 45 | $657 |
| AstraZeneca | 32 | $530 |
| Boehringer Ingelheim | 17 | $402 |
| Lantheus Medical Imaging, Inc. | 18 | $400 |
| Abbott | 7 | $383 |
| Inari Medical, Inc. | 12 | $381 |
| Boston Scientific | 5 | $319 |
| E.r. Squibb & Sons, L.L.C. | 16 | $258 |
| Heartflow, Inc. | 3 | $254 |
| Edwards Lifesciences | 2 | $250 |
| Merck | 9 | $220 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $215 |
| Sanofi-aventis U.S. LLC | 6 | $199 |
| Pfizer | 7 | $126 |
| Bridgebio Pharma, Inc. | 1 | $124 |
| Amarin Pharma, Inc. | 8 | $120 |
| Biotronik Inc. | 1 | $99 |
| Alnylam Pharmaceuticals Inc. | 2 | $44 |
| Esperion Therapeutics, Inc. | 3 | $43 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
| Scpharmaceuticals Inc. | 1 | $24 |
| Cvrx, Inc. | 1 | $24 |
| Cardiva Medical, Inc. | 1 | $15 |
| W. L. Gore & Associates, Inc. | 1 | $14 |
| Gilead | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$79,314
- ENTRESTO$11,444
- PAINTEQ$702
- Veltassa$338
- FFRct$238
- SAPIEN 3 Ultra RESILIA$232
- FLOWTRIEVER CATHETER, S$166
- CT THROMBECTOMY SYSTEM KIT$166
- CARDIOMEMS$152
- Attruby$124
- JARDIANCE$119
- PRALUENT$114
- Watchman$112
How this compares
$100,468 in reported general payments places this provider in the 95th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 785 | $972,165 |
| XareltoRivaroxaban | 320 | $426,202 |
| EntrestoSacubitril/Valsartan | 186 | $287,084 |
| Repatha SureclickEvolocumab | 264 | $268,733 |
| FarxigaDapagliflozin Propanediol | 127 | $130,682 |
| Praluent PenAlirocumab | 72 | $61,733 |
| JardianceEmpagliflozin | 39 | $54,565 |
| BrilintaTicagrelor | 52 | $52,938 |
| VascepaIcosapent Ethyl | 65 | $48,915 |
| VeltassaPatiromer Calcium Sorbitex | 14 | $23,583 |
| Atorvastatin Calcium | 2,693 | $22,146 |
| MultaqDronedarone Hcl | 12 | $21,030 |
| Potassium Chloride | 515 | $18,698 |
| Ezetimibe | 658 | $14,311 |
| NexlizetBempedoic Acid/Ezetimibe | 12 | $12,018 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $126 | $972,165785 claims |
| Johnson & JohnsonXarelto | $657 | $426,202320 claims |
| NovartisEntresto | $12,684 | $287,084186 claims |
| AstraZenecaFarxiga, Brilinta | $530 | $183,619179 claims |
| Boehringer IngelheimJardiance | $402 | $54,56539 claims |
| Sanofi-aventis U.S. LLCMultaq | $199 | $21,03012 claims |
| Esperion Therapeutics, Inc.Nexlizet | $43 | $12,01812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 408 cardiovascular disease providers in Indiana.
Other cardiovascular disease in Valparaiso
- John MillerIndianapolis$354K
- David KovacichIndianapolis$327K
- Wai LeeElkhart$321K
- Anas SafadiHobart$295K
- Lawrence RinkBloomington$280K
- Vijay RaoIndianapolis$247K
- Steven SteinhublLafayette$247K
- Atul ChughIndianapolis$242K
- James TrippiIndianapolis$239K
- Christopher HealyIndianapolis$209K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.